Search Results

You are looking at 41 - 50 of 65 items for :

  • "pituitary adenoma" x
Clear All
Open access

Pinaki Dutta, Bhuvanesh Mahendran, K Shrinivas Reddy, Jasmina Ahluwalia, Kim Vaiphei, Rakesh K Kochhar, Prakamya Gupta, Anand Srinivasan, Mahesh Prakash, Kanchan Kumar Mukherjee, Viral N Shah, Girish Parthan and Anil Bhansali

of radiotherapy increases in acromegaly patients (3) . The prevalence of GHD is higher in treated acromegaly patients as compared with patients with nonfunctioning pituitary adenomas treated with similar modalities (15% vs 5%) (4) . GHD in adulthood

Open access

Marcus Quinkler, Bertil Ekman, Claudio Marelli, Sharif Uddin, Pierre Zelissen, Robert D Murray and on behalf of the EU-AIR Investigators

2009 94 4216 – 4223 . ( doi:10.1210/jc.2009-1097 ) 32 Zueger T Kirchner P Herren C Fischli S Zwahlen M Christ E Stettler C. Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma

Open access

Lauren Bell, Ann Louise Hunter, Angelos Kyriacou, Annice Mukherjee and Akheel A Syed

gonadotrophin (hCG) ( 4 ), and TSH-producing pituitary adenomas. Graves’ disease, the commonest cause of hyperthyroidism, has an annual incidence of 20–50 per 100,000 population, a peak incidence between 30 and 50 years of age, and a lifetime risk of 3% for

Open access

Lijin Ji, Na Yi, Qi Zhang, Shuo Zhang, Xiaoxia Liu, Hongli Shi and Bin Lu

. Diagnosis and treatment of pituitary adenomas: a review . JAMA 2017 317 516 – 524 . ( ) 28170483 10.1001/jama.2016.19699 4 Vilar L Naves LA Casulari LA Azevedo MF Albuquerque JL Serfaty FM Pinho Barbosa FR de

Open access

L M Mongioì, R A Condorelli, S La Vignera and A E Calogero

Vitiligo, non-secreting pituitary adenoma, vitamin D deficiency, chronic autoimmune thyroiditis, overweight Cortisone acetate 50 mg/day 30 6 M 59 Bilateral surrenectomy Hypogonadism, overweight Hydrocortisone 40 mg/day 32 7 M

Open access

Roxanne C S van Adrichem, Aart Jan van der Lely, Martin Huisman, Piet Kramer, Richard A Feelders, Patric J D Delhanty and Wouter W de Herder

Burrin JM Dahia PL Monson JP Honegger J Fahlbush R Trainer PJ Chew SL Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors . Journal of

Open access

Ursula M M Costa, Carla R P Oliveira, Roberto Salvatori, José A S Barreto-Filho, Viviane C Campos, Francielle T Oliveira, Ivina E S Rocha, Joselina L M Oliveira, Wersley A Silva and Manuel H Aguiar-Oliveira

Burchell L Rajan B 2002 Cerebrovascular mortality in patients with pituitary adenoma . Clinical Endocrinology 57 713 – 717 . doi:10.1046/j.1365-2265.2002.01570.x . 8 Gaillard RC Mattsson AF Akerblad AC Bengtsson BA Cara J Feldt

Open access

David P Sonne, Asger Lund, Jens Faber, Jens J Holst, Tina Vilsbøll and Filip K Knop

various human pituitary adenomas . European Journal of Endocrinology 2002 147 263 – 268 . ( doi:10.1530/eje.0.1470263 ). 27 Salvatore D Bartha T Harney JW Larsen PR . Molecular biological and biochemical characterization of the human type 2

Open access

Charlotte Höybye, Erik Wahlström, Petra Tollet-Egnell and Gunnar Norstedt

Pituitary apoplexi M 59 3 −0.7 28.2 100 IGF1, insulin-like growth factor 1; NFPA, non-functioning pituitary adenomas; TBI, traumatic brain injury. Healthy controls At baseline, the patients with GHD were compared with ten age- and gender-matched healthy

Open access

Soraya Puglisi, Paola Perotti, Mattia Barbot, Paolo Cosio, Carla Scaroni, Antonio Stigliano, Pina Lardo, Valentina Morelli, Elisa Polledri, Iacopo Chiodini, Giuseppe Reimondo, Anna Pia and Massimo Terzolo

Introduction Cushing’s syndrome (CS) is a condition of endogenous hypercortisolism caused by different pathological entities that is classified in two variants: (i) ACTH-dependent CS, due to a corticotroph pituitary adenoma or an ectopic tumor